Antibody Discovery Market Research, 2032
The global antibody discovery market size was valued at $6.9 billion in 2022, and is projected to reach $17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032. Antibody discovery is defined as the process of identifying new antibody. This process involves searching for antibodies that recognize and bind to the target and can be used for diagnostic or therapeutic purposes. Techniques such as phage display and hybridoma technology are commonly used for antibody discovery. This process is important for the development of new drugs, vaccines, diagnostics, and other therapeutic applications by allowing researchers to create specific antibodies that can recognize and target specific antigens. Different types of antibodies are produced such as humanized antibody, human antibody, chimeric antibody, and murine antibody.
Market Dynamics
Growth of the global antibody discovery market size is majorly driven by increase in investment in R&D activities of antibody discovery, surge in prevalence of infectious & chronic diseases, growth in awareness among individuals regarding early diagnosis detection, and personalized medicine. The market has expanded as a result of rising R&D spending on antibody discovery and the rise in demand for more efficient, cost-effective, and effective treatments for a variety of diseases. Since antibodies can be modified to target particular pathogens and can be administered with few side effects, they present a hopeful method for treating diseases. For instance, Abzena, a top supplier of biologics and antibody drug conjugates, stated in September 2022 that it would expand its research and development capabilities in Cambridge to support the advancement of rapid antibody discovery. Moreover, Bio-Rad, a pharmaceutical company, provide 10,000 antibodies along with antigen, reagent, buffer for the development of research and in vitro diagnostic assay. Thus, pharmaceutical companies are investing more heavily in R&D activities related to antibody discovery to develop better treatments for a variety of diseases.
A significant factor that drives the worldwide market for antibody discovery is the alarming rise in the prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune diseases, and presence of antibody discovery industry. The increase in prevalence of chronic disease augments the need for effective treatment, which drives the demand for antibody discovery services. Globally, chronic illnesses such as diabetes and cardiovascular disease are the main contributors to morbidity and death. The World Health Organization (WHO) stated that 77% of chronic disease-related deaths in 2021 occurred in low- and middle-income countries. Thus, the need for developing high-quality antibodies is increased by the rise in the prevalence of chronic illnesses.
Moreover, rise in prevalence of infectious disease and availability of therapeutic antibody for infectious disease, is one of the major factors for the growth of the market. For instance, according to the Multidisciplinary Digital Publishing Institute (MDPI), in 2020, it was reported that each year around 30 million people were detected with bloodstream infection. According to the World Health Organization (WHO), in 2020, 85% of the deaths from sepsis occur in low and middle income countries. In addition, the rise in prevalence of HIV, which is a global public health issue, fosters the demand for therapeutic antibody. thus, rise in prevalence of infectious disease, and chronic diseases propels the demand for antibody discovery and boosts the growth of the market.
In addition, rise in concern regarding health and increase in demand for early diagnostic testing drive the growth of the global market. Furthermore, the increased awareness of personalized medicine among consumers is expected to continue to drive the growth of the antibody discovery market forecast period. Personalized medicine is the tailoring of medical treatment by using available biological information through biomarker and genetic testing. Personalized medication aims to design the antibodies, which can be customized to target specific pathogens.
Various awareness programs are conducted on early diagnosis for timely and better treatment, which surge the demand for various diagnostic testing such as oncology testing, and immunology testing. For instance, in January 2021, Fortis Memorial Research Institute organized a health camp in order to create awareness and provide knowledge to people about the importance of regular screening for early diagnosis and better treatment. Thus, rise in awareness among individuals for early diagnosis and personalized medicine propels the growth of the antibody discovery market.
On the other hand, high costs associated with antibody discovery process is anticipated to limit adoption of the market during the forecast period. For instance, according to the Biomatik, it was reported that the average cost for the production of monoclonal antibody lies between $6,000 to $15,000. High cost is a major hindrance in for pharmaceutical and biopharmaceutical companies. Thus, this factor is expected to hamper the market growth during the forecast period.
The COVID-19 pandemic had a significant impact on antibody discovery. Through increased investment in research, the development of new technologies, and the adoption of innovative strategies, scientists have made significant progress toward the discovery of effective and targeted antibodies. Thus, the COVID-19 outbreak is anticipated to have a positive impact on the growth of the global antibody discovery market.
Segmental Overview
The antibody discovery market is segmented into Methods, Antibody Type, End Users, and Regions. On the basis of method, the market is classified into phage display, hybridoma, and others. On the basis of antibody type, the market is divided into humanized, human, chimeric, and murine antibody. On the basis of end user, the market is categorized into pharmaceutical and biotechnology industry, research laboratory, and academic laboratory. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Method
On the basis of method, the antibody discovery market share is classified into phage display, hybridoma, and others. The others include single cell-based method, and transgenic mouse method. The phage display segment was the largest revenue contributor to the market in 2022 due to advantage of phage display method over other antibody discovery method.
By Antibody Type
On the basis of antibody type, the antibody discovery market share is classified into humanized, human, chimeric, and murine. The humanized antibody segment was the highest revenue contributor to the market in 2022 and is the fastest growing segment during the forecast period, due to rise in acceptance and adoption of human antibody drug. Human antibodies are more specific, stable, and cost-effective than murine, chimeric, and humanized antibodies.
By End User
On the basis of end user, the market is classified into pharmaceutical and biotechnology industry, research laboratory, and academic laboratory. The pharmaceutical and biotechnology industry segment dominated the market in 2022 and is expected to continue this trend throughout the forecast period, owing to rise in the R&D activities in pharmaceutical and biotechnology industry, and rise in expenditure by government to develop advanced pharmaceutical and biotechnology sector.
By Region
North America antibody discovery market is expected to grow during the forecast period owing to rise in prevalence of cancer, strong presence of antibody discovery industry and advancement in technology in R&D sector. For instance, according to American Cancer Society, in 2020, it was reported that around 1.8 million new cancer cases are diagnosed and about 606,520 cancer deaths observed in the U.S... This surge the need for therapeutic antibody and drive the antibody discovery market growth.
Rise in funding allows for the development of new technologies, the pooling of resources and expertise across countries and organizations, and the exploration of existing antibody treatments. This has resulted in a greater understanding of the immune system and how to develop effective and targeted antibodies. Additionally, the increased funding has enabled scientists to conduct large-scale clinical trials necessary to evaluate the efficacy of a particular antibody. Thus, the rise in funding for research and development activities is attributed to boost the growth of the market.
Asia-Pacific antibody discovery market is expected to witness growth during the forecast period owing to rise in prevalence of cardiovascular diseases and other chronic diseases. According to the Journal of Biomedical and Environmental Science, 2021 around 330 million people suffered from cardiovascular diseases in China. Antibody discovery is crucial in the development of novel therapeutics for cardiovascular diseases. Thus, the increase in prevalence of heart disease surges the need for antibody discovery and drive the growth of the market.
Research centers are essential for the development and testing of novel antibodies. These centers can be used to conduct research on antibody sequences, develop new and novel antibodies, and optimize existing antibodies. According to the Scimago Institute Ranging, in 2022, it was reported that around 170 research centers for medicine are present in China, 72 research center are present in Japan, 17 research center in India, and 53 research center in Australia. Thus, the presence of research centers in Europe is an important factor driving the growth of the antibody discovery market.
Competition Analysis
Some of the major companies that operate in the antibody discovery market include Genscript Technology, Danaher Corporation, Twist Bioscience HQ, Sartorius AG, Charles River Laboratories, Eurofins Discovery, Fairjourney Biologics SA, Biocytogen, Creative Biolab, and Evotec.
Recent R&D strategies in the Antibody Discovery Market
- In September 2022, Abzena, one of the leading providers for discovery, development and manufacturing of biologics and antibody drug conjugates, announced to increase its R&D capabilities in Cambridge, to support the development of rapid antibody discovery.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody discovery market analysis from 2022 to 2032 to identify the prevailing antibody discovery market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antibody discovery market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antibody discovery market trends, key players, market segments, application areas, and market growth strategies.
Antibody Discovery Market, by Methods Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 17.2 billion |
 Growth Rate | CAGR of 9.6% |
 Forecast period | 2022 - 2032 |
 Report Pages | 252 |
 By Methods |
|
 By Antibody Type |
|
 By End Users |
|
 By Region |
|
 Key Market Players | Eurofins Scientific, Charles River Laboratories, Fairjourney Biologics S.A, Creative Biolabs, Biocytogen, Twist Bioscience, Danaher Corporation, Evotec, Sartorius AG, Genscript Technology Corporation |
Analyst Review
Antibody discovery is defined as the process by which antibodies are produced by the immune system to recognize and neutralize foreign substances. This process typically involves the use of various techniques, such as phage display and high-throughput screening, to identify and isolate antibodies that recognize a specific antigen.
Rise in antibody discovery services in various pharmaceutical and biotechnology industry augments market growth. For instance, in March 2023, Biocytogen Pharmaceuticals, a biotechnology company, announced an agreement with Janssen Biotech, Inc., a pharmaceutical company of Jonson & Johnson. Under the agreement, Biocytogen offers license to Jassen for the use of Biocytogen’s proprietary RenLite platform. This platform aims to conduct research, commercialize, and manufacture human antibody therapy. Moreover, in January 2023, Biocytogen Pharmaceuticals, announced an antibody collaboration, assignment, and exclusive license agreement with Hansoh Pharmaceutical Group Company Limited. Under this agreement, biogen provides license to Hansoh Pharma, for its human antibody molecules for the development and manufacturing of antibody globally.
The top companies that hold the market share in antibody discovery market are Genscript Technology, Danaher Corporation, Twist Bioscience HQ, Sartorius AG, Charles River Laboratories, Eurofins Discovery, Fairjourney Biologics SA, Biocytogen, Creative Biolab, and Evotec
Asia-Pacific is anticipated to witness lucrative growth during the forecast period, owing to increase in R&D activities in pharmaceutical and biotechnology sector, presence of various healthcare research centers, and increase in investment for drug discovery.
The key trends in the antibody discovery Market are to increasing investment in R&D activities of antibody discovery, surge in prevalence of infectious and chronic disease, and growth in awareness among individuals regarding early diagnosis detection and personalized medicine
The base year for the report is 2022.
North America is the largest regional market for Antibody Discovery market
The total market value of antibody discovery Market market is $6,869.5 million in 2022 .
The forecast period in the report is from 2023 to 2032
Major restraints in the antibody discovery market are high cost of antibody discovery
Loading Table Of Content...
Loading Research Methodology...
